RELMADA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Prepaid Expense and Other Assets of $319.87 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $7.50K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $493.12K, a 51.45% decline year-over-year.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was -$121.78K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-03-31 was -$290.05K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $88.78K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$319.75K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$2.84M.
- RELMADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$7.26M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $319.87K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $7.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $500.62K derived: sum of 2 quarters · filed 2026-03-19 | $378.84K derived: sum of 3 quarters · filed 2026-08-06 | $88.78K 10-K · filed 2026-03-19 |
| 2025-09-30 | $493.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $371.34K derived: sum of 2 quarters · filed 2026-08-06 | $81.28K 10-Q · filed 2025-11-13 | -$617.06K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$121.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$411.83K 10-Q · filed 2026-08-06 | -$1.11M derived: sum of 3 quarters · filed 2026-08-06 | -$94.55K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$290.05K 10-Q · filed 2025-05-12 | -$988.39K derived: sum of 2 quarters · filed 2026-03-19 | $27.24K derived: sum of 3 quarters · filed 2026-03-19 | -$177.07K derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-12-31 | -$698.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $317.29K derived: sum of 2 quarters · filed 2026-03-19 | $112.98K derived: sum of 3 quarters · filed 2026-03-19 | -$319.75K 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $811.32K derived: sum of 2 quarters · filed 2025-11-13 | $378.60K 10-Q · filed 2025-11-13 | -$1.27M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$204.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$637.03K 10-Q · filed 2025-08-07 | -$2.29M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$432.72K 10-Q · filed 2025-05-12 | -$2.09M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$2.84M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$1.19M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$7.26M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |